Cerepro, 400 mg capsules, 28 pcs.

A centrally acting cholinomimetic containing 40.5% metabolically protected choline (metabolic protection promotes choline release in the brain).

On entering the body it is split by the action of enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine – one of the main mediators of neural excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane.

The drug provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in CNS, activates reticular formation; increases the linear velocity of blood flow on the side of the traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular disease.

The drug improves brain functions, influencing pathogenetic factors of involutional psychoorganic syndrome, changes phospholipid composition of neuronal membranes and reduces cholinergic activity.

Dose-dependently stimulates acetylcholine release by participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, neuronal membrane plasticity, receptor function.

Indications

– acute and recovery periods of severe traumatic brain injury and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;

— psychoorganic syndrome against the background of degenerative and involutional changes in the brain;

— chronic cerebral circulatory failure;

– cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), incl. for dementia and encephalopathy;

– senile pseudomelancholy.

Pharmacological effect

Centrally acting cholinomimetic, which contains 40.5% metabolically protected choline (metabolic protection promotes the release of choline in the brain).

When it enters the body, it is broken down by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor to phospholipids (phosphatidylcholine) in the neuronal membrane.

The drug ensures the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation; increases the linear speed of blood flow on the side of the traumatic brain injury, helps to normalize the spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain.

The drug improves brain function by affecting the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity.

Dose-dependently stimulates the release of acetylcholine, participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, and receptor function.

Active ingredient

Choline alphoscerate

Composition

1 caps. Choline alfoscerate (glycerylphosphorylcholine hydrate) 400 mg.

Excipients:

glycerol (glycerin),

purified water.

Composition of the capsule shell:

medical gelatin,

glycerol (glycerol),

methyl parahydroxybenzoate (methylparaben),

propyl parahydroxybenzoate (propylparaben),

iron oxide red dye,

titanium dioxide,

purified water,

sorbitol (sorbitol).

Contraindications

– pregnancy;

– lactation period (breastfeeding);

– hypersensitivity to the components of the drug.

Side Effects

From the digestive system: nausea (as a result of dopaminergic activation).

Other: allergic reactions.

Interaction

Drug interactions with Cerepro have not been established.

Overdose

Symptoms: dyspepsia.

Treatment: gastric lavage, taking activated carbon, symptomatic therapy.

Storage conditions

In a dry place, protected from light and out of reach of children, at a temperature of 25°C.

Manufacturer

Veropharm LLC, Russia